HF, the inability of the heart to pump blood, has no definitive treatment except heart transplantation or Ventricular Assist Device^[@R3]^. In HF, physiologic compensatory mechanisms place strain on cardiomyocytes and promote cardiomyocyte loss and fibrosis in pathologic remodeling^[@R4]--[@R6]^. Hippo pathway activation, including Mst and Lats kinases and Salvador (*Salv*) adaptor, results in phosphorylation and nuclear exclusion of transcriptional cofactors Yap and Taz that cooperatively bind DNA with Tead factors^[@R2],[@R7]^. Concurrent *Salv* or *Lats1* and *Lats2* deletion with myocardial infarct (MI) improves heart function^[@R8]--[@R10]^. Yap target genes control proliferation, cytoskeletal remodeling, and protect plasma membrane from contractile stress^[@R9]^. Maladaptive activation of Hippo signaling occurs in human HF and mouse ischemia reperfusion^[@R11],[@R12]^. To determine if endogenous cardiomyocyte renewal can be increased in HF, we deleted *Salv* in a mouse model of ischemic HF (iHF) post-MI. The Hippo pathway represses a reparative genetic program in iHF that includes cardiomyocyte proliferation and survival genes.

Western blots on iHF and nonischemic HF (HF) human samples revealed that pYap and pLats serine 909 levels were higher and Salv levels unchanged in iHF and HF than controls ([Fig. 1a-f](#F11){ref-type="fig"}, [Extended Data Fig. 1a-c](#F1){ref-type="fig"}). We generated *αMHC-mcm*;*Salv ^f/f^* (*SalvCKO*) mice with iHF post-MI ([Fig. 2a](#F12){ref-type="fig"}). Echocardiography three weeks post-MI before tamoxifen, revealed shams had an average ejection fraction (EF) of 64±12% and fractional shortening (FS) of 35±8% ([Fig. 2a-c](#F12){ref-type="fig"}). Post-MI, mice had an average EF of 36±11% and FS of 18±6% ([Fig. 2a-c](#F12){ref-type="fig"})^[@R13]^. End-systolic variables showed increased systolic left ventricle (LV) chamber diameters (Sham 2.7+/−0.6mm, MI 4.1±0.5mm) and volumes (Sham 29+/−18μL, MI 76±23μL) ([Extended Data Fig. 2a-d](#F2){ref-type="fig"}). Diastolic indices were unchanged indicating iHF was a result of systolic dysfunction ([Extended Data Fig. 2b, d](#F2){ref-type="fig"}). Other iHF signs included pulmonary fluid buildup, hemosiderin-laden macrophages, increased natriuretic peptide B (BNP) serum levels, and increased body weights ([Extended Data Fig. 2e-j](#F2){ref-type="fig"}).

3 weeks post-MI, we deleted *Salv* in cardiomyocytes and performed echocardiography every 2 weeks until 9 weeks post-MI (6 weeks after tamoxifen injection) ([Fig. 2a-c](#F12){ref-type="fig"}, [Extended Data Fig. 2a-d, k, l](#F2){ref-type="fig"}). At 9 weeks post-MI, *SalvCKO* had improved function (EF; *SalvCKO* MI 59%±13%, Ctrl MI 38±9%, p=0.001) similar to sham controls (EF; *SalvCKO* MI 59%±13%, Ctrl and *SalvCKO* Sham 65%±8%, p=1)([Fig. 2c](#F12){ref-type="fig"}).

9 week post-MI control hearts had remodeled scars whereas *SalvCKO* hearts showed less fibrosis and more LV cardiomyocytes (fibrosis: Ctrl 56±12%, *SalvCKO* 36 ±15%; CM number: Ctrl 1×10^5^±8×10^4^, *SalvCKO* 6×10^5^±2×10^5^) ([Fig. 2d-j](#F12){ref-type="fig"}). We defined three qualitative categories of damage in *SalvCKO* hearts post-MI ([Fig. 2d, e](#F12){ref-type="fig"}). Category I, observed in 10% of *SalvCKO* cohort (N=1 of 10), recovered most LV cardiomyocytes. Category II, observed in 80% of *SalvCKO* hearts (N=8 of 10), had an equal amount of fibrotic and cardiomyocyte area in LV. Category III, observed in 10% of *SalvCKO* hearts, had few LV cardiomyocytes with a remodeled scar (N=1 of 10) ([Fig. 2d-f](#F12){ref-type="fig"}). The relationship between fibrosis and function was described by a second order polynomial suggesting that fibrosis is tolerated to maintain cardiac function ([Fig. 2g](#F12){ref-type="fig"}).

3 weeks post-MI, all hearts had LV infarcts, ([Extended Data Fig. 3](#F3){ref-type="fig"}). At two time points, hearts were collected one week prior to echocardiography for histopathology. We discuss those time points as a 2 week range (ie. 4-5 and 6-7 weeks post-MI). There were no differences between groups at 4-5 weeks and 6-7 weeks post-MI ([Fig. 2b, c, f](#F12){ref-type="fig"}, [Extended Data Fig. 4](#F4){ref-type="fig"},[5](#F5){ref-type="fig"}). At 6 weeks post-MI, *Myh7, Nppa*, and *Nppb*, associated with adult cardiomyocyte remodeling, were upregulated in control iHF but not *SalvCKO* ([Extended Data Fig. 6a](#F6){ref-type="fig"}).

*SalvCKO* hearts at 6 weeks post-MI had a three fold increase in BZ capillary density and increased endothelial markers, isolectin B4 and CD-31 compared to controls ([Extended Data Fig. 6b-e](#F6){ref-type="fig"}). Cardiomyocyte-enriched TRAP RNA revealed increased vasculogenesis genes encoding angiopoietins, fibroblast growth factors, and vascular endothelial growth factors in cardiomyocytes of *SalvCKO* MI hearts ([Extended Data Fig. 6f](#F6){ref-type="fig"}).

We found *SalvCKO* hearts had 2% to 3% cardiomyocyte EdU incorporation at 4 and 6 weeks post-MI and approximately 1% at 9 weeks post-MI ([Fig. 2k, l](#F12){ref-type="fig"}). Phospho-histone H3 IF revealed M-phase cardiomyocytes 9 weeks post-MI in *SalvCKO* MI mice ([Fig. 2m, n](#F12){ref-type="fig"}). Hence, cardiomyocyte cell cycle entry was diminished in *SalvCKO* mouse hearts at 9 weeks post-MI as cardiomyocytes repaired the tissue defect.

Lineage tracing by *αMHC-mcm* transgene revealed mosaic labeling of BZ cardiomyocytes ([Fig. 2o](#F12){ref-type="fig"}). At 4-weeks post-MI, BZ had equivalent numbers of GFP-positive cardiomyocytes in controls (33%±7%) and *SalvCKO* (22%±2%) ([Fig. 2o, p](#F12){ref-type="fig"}). At 9-weeks post-MI GFP-positive BZ cardiomyocytes were enriched in *SalvCKO* (Ctrl MI 41%±6%, *SalvCKO* MI 91%±4%) ([Fig. 3o, p](#F13){ref-type="fig"}) indicating that most new, reparative BZ cardiomyocytes are derived from pre-existing cardiomyocytes rather than *Myh6*-negative cardiac stem cells that would be GFP-negative. Cardiomyocyte cross-sectional area was reduced, suggesting a more primitive phenotype, in *SalvCKO* mice at 9 weeks post-MI^[@R14]^ ([Fig. 2q](#F12){ref-type="fig"}).

We sequenced Total-RNA and TRAP-RNA from BZ 6 weeks post-MI ([Extended Data Fig. 7a-d](#F7){ref-type="fig"}). Total-RNA revealed upregulated genes (N=932) in *SalvCKO* BZ were involved in oxidative phosphorylation, RNA processing, stress response, cell cycle, and muscle contraction ([Fig. 3a-c](#F13){ref-type="fig"}, [Extended Data Fig. 8a](#F8){ref-type="fig"}). *SalvCKO* BZ downregulated genes (N=792) included developmental genes, glycolytic metabolism genes, and connective tissue genes including pro-fibrotic genes like *Tgfbr1, Ctgf*, and *Pdgfrδ* ([Fig. 3d](#F13){ref-type="fig"}, [Extended Data Fig. 8a](#F8){ref-type="fig"})^[@R15],[@R16]^.

Comparison of TRAP-seq, enriched for cardiomyocyte translating RNA ([Fig. 3e,f](#F13){ref-type="fig"}), to total RNA-seq revealed that TRAP-seq was enriched for cardiomyocyte genes and depleted of non-cardiomyocyte genes ([Fig. 3g-i](#F13){ref-type="fig"}, [Extended Data Fig. 8b](#F8){ref-type="fig"}). Non-translated LncRNAs were depleted from TRAP-seq ([Fig. 4I](#F14){ref-type="fig"}, [Extended Data Fig. 8b](#F8){ref-type="fig"}). Comparison of total RNA-seq to TRAP-seq revealed total RNA and TRAP-seq groups clustered separately ([Fig. 3j](#F13){ref-type="fig"}). *SalvCKO* MI TRAP-seq clustered closely to control sham TRAP-seq data revealing that Hippo deficient cardiomyocytes expressed a genetic program similar to control shams ([Fig. 3j](#F13){ref-type="fig"}).

We compared TRAP-seq of control post-MI and sham (Ctrl MI vs Ctrl Sham) to determine cardiomyocyte gene expression changes during iHF post-MI ([Extended Data Fig. 8c-f](#F8){ref-type="fig"}). One upregulated category was peptide metabolic processes including *Akt1* that exacerbates HF when chronically expressed^[@R17]^([Extended Data Fig. 8d, f](#F8){ref-type="fig"}). Genes that respond to reactive oxygen species, such as *GstP1* and *Gpx3*, were upregulated as was *Clusterin*, known to be upregulated in human HF^[@R18]^. Another upregulated gene category, actin filament based process, is consistent with observations that cytoskeletal components are upregulated in human HF^[@R19]^. Downregulated gene categories included chromatin organization and blood vessel development consistent with known gene expression changes in HF^[@R20],[@R21]^([Extended Data Fig. 8e, f](#F8){ref-type="fig"}). Genes involved in organelle fission, such as mitochondrial fission, were downregulated. Disruption of mitochondrial fission and fusion can lead to HF^[@R22]^ ([Extended Data Fig. 8e, f](#F8){ref-type="fig"}).

We compared TRAP-seq between *SalvCKO* and control hearts post-MI (*SalvCKO* MI vs Ctrl MI) ([Fig. 3f](#F13){ref-type="fig"}). Upregulated genes (N=365) included cell cycle genes, consistent with previous studies ([Fig. 3k](#F13){ref-type="fig"}, [Extended Data Fig. 8g](#F8){ref-type="fig"})^[@R8],[@R9]^. Other upregulated genes included genes involved in heart contraction, heart growth, and cellular response to stress suggesting that *SalvCKO* cardiomyocytes were recovering the mature cardiomyocyte phenotype with an effective stress response. Downregulated genes (N=261) in *SalvCKO* cardiomyocytes post-MI included translation, protein metabolism including ubiquitin-proteosome pathway, and inflammation ([Fig. 3l](#F13){ref-type="fig"}, [Extended Data Fig. 8g](#F8){ref-type="fig"}), indicating that inflammation and mis-folded protein response were more effectively resolved in *SalvCKO* MI.

*Park2*, a Yap target gene, was upregulated in *SalvCKO* TRAP-seq ([Fig. 3m](#F13){ref-type="fig"})^[@R9]^. *Park2* encodes a ubiquitin ligase involved in MQC, a surveillance mechanism to recycle damaged mitochondria^[@R23]^. Park2 is recruited to damaged mitochondria to direct mitochondria into mitophagy pathway that salvages damaged mitochondria. Park2 protein levels are reduced in human HF ([Fig. 4a,b](#F14){ref-type="fig"} [Extended Data Fig. 9a-c](#F9){ref-type="fig"}). Moreover, *Park2* deletion in adult mice results in dilated cardiomyopathy post-MI^[@R24]^. Similar to Yap, *Park2* is required for P1 cardiac regeneration ([Extended Data Fig. 9d-i](#F9){ref-type="fig"})^[@R25]^.

We tested if *Park2* was required for regeneration in P8 *SalvCKO*^[@R8]^. After P8 MI, *SalvCKO* had higher mitochondrial DNA content and increased Park2 protein levels ([Extended Data Fig. 10a,b](#F10){ref-type="fig"}), suggesting that MQC is more active in *SalvCKO* hearts. *Park2* was required for recovery of myocardial function in *SalvCKO* hearts after P8 MI, ([Extended Data Fig. 10c-g](#F10){ref-type="fig"}). Interestingly, although myocardial function was reduced, fibrosis did resolve in *SalvCKO*;*Park2^−/−^* hearts, indicating a myocardial-autonomous requirement for *Park2* in *SalvCKO* neonatal hearts ([Extended Data Fig. 10c, g](#F10){ref-type="fig"}).

*Park2* was required for cardiac function recovery in adult iHF ([Fig. 4c-g](#F14){ref-type="fig"}). Compared to *SalvCKO* mice, double mutant *SalvCKO*;*Park2−/−*mice didn't recover contractile function ([Fig. 4c,d](#F14){ref-type="fig"}). However, unlike *SalvCKO* adult hearts and *SalvCKO*;*Park2−/−* neonatal hearts ([Extended Data Fig. 10c](#F10){ref-type="fig"}), scar failed to resolve in *SalvCKO*;*Park2−/−* adult hearts revealing a differential requirement for *Park2* in neonatal versus adult fibrosis resolution ([Fig. 4e-g](#F14){ref-type="fig"}).

We engineered a viral vector to knockdown *Salv* in cardiomyocytes ([Fig. 4h, i](#F14){ref-type="fig"}). Direct myocardial viral injection at the time of MI or systemic viral injection 3 weeks post-MI resulted in improved cardiac function and cell cycle induction ([Fig. 4j-o](#F14){ref-type="fig"}). Hippo pathway inhibition, genetically or with gene therapy, results in an effective stress response in iHF with organ failure reversal.

Since Hippo signaling is upregulated in human iHF, Hippo pathway inhibition may have a therapeutic benefit for iHF patients. We identified cardiomyocyte-directed, non-cell-autonomous injury responses that improve vascular perfusion. New cardiomyocytes, derived from pre-existing cardiomyocytes, direct recovery of a BZ microvasculature by expressing vessel-promoting factors including FGF's that are protective against cardiac damage^[@R26]--[@R28]^. iHF reversal requires a proliferative response and injury resistance since newly generated cardiomyocytes must withstand both mechanical and hypoxic stress. At risk cardiomyocytes also likely benefit from Hippo pathway inhibition.

Our data provide insight into *Park2* function in cardiac regeneration. In addition to MQC, *Park2* functions in mitochondrial maturation and in fetal-to-adult metabolic transition^[@R29]^. *Park2* is essential for neonatal regeneration and for cardiac repair in non-regenerative P8 *SalvCKO* hearts and in iHF. In P8 *SalvCKO* hearts, *Park2* deletion was detrimental to cardiac function, but dispensable for fibrosis resolution. In contrast, in adult iHF, both cardiac function and fibrosis resolution were impaired in *SalvCKO;Park2^−/−^* mice. *Park2* requirements in cardiomyocyte function and fibrosis resolution are an area of future study.

Materials and Methods {#S1}
=====================

Patient Samples {#S2}
---------------

Three types of human heart tissue samples were used for this study: control samples (nonfailing, nontransplantable hearts, n=6), HF samples (hearts with nonischemic idiopathic cardiomyopathy in end-stage failure, n=3), and iHF samples (hearts with ischemic heart disease in end-stage failure, n=3). For Control and both types of HF, samples were obtained from the left ventricular apex. The HF samples were collected at the time of left ventricular assist device implantation, the area from which the tissue core is obtained. The tissue samples were provided by the Texas Heart Institute (THI) Center for Cardiac Support Cardiovascular Surgery Research and Cardiovascular Pathology Research in accordance with human research protocol approved by the Texas Heart Institute Institutional Review Board under which patient informed consent was obtained. Sample analysis was conducted in accordance with human research protocol approved by the Baylor College of Medicine Institutional Review Board for which additional patient consent was waived. The tissue samples were digested to obtain protein lysates with the following buffer: 50mM Tris-Cl (pH7.5), 150mM NaCl, 1% Triton X-100, 0.25% sodium deoxycholate, and protease/phosphatase inhibitors. Samples were homogenized with a Dounce tissue homogenizer, passed through a 22-gauge needle, and sonicated for 10 cycles (30 seconds on, 30 seconds off) in a Diagenode Bioruptor Pico Plus NGS. For western blot analysis, we used antibodies against total YAP (Novus \# NB110-58358), pYAP (Cell Signaling \# 4911S), pLats1 (Cell Signaling \# 9157), Sav1 (Novus \# NBP2-13282), Park2 (Cell Signaling \# 2132S), and alpha-tubulin (Sigma \# T5168).

Mice {#S3}
----

Adult C57/BL6×129/S mice, 8 to 10 weeks old were used for the heart failure studies, and underwent either a Sham procedure or an MI procedure. C57/BL6 and 129/S strains are weakly regenerative strains^[@R30]^. For the AAV9 experiments, adult (8-10 week old) ICR (CD1) mice were used. The regenerative characteristics of outbred ICR (CD1) compared to inbred strains has not been systematically investigated. At 3 weeks post-MI, we injected tamoxifen into mice to induce Cre activity in cardiomyocytes. Control (Ctrl) mice included tamoxifen-injected αMHC-mcm; ROSA^mT/mG^(mTmG) mice, tamoxifen-injected *Salv^fl/f^*^l^ mice, and oil-injected αMHC-mcm; *Salv^fl/f^*^l^ mice to control for Tamoxifen and cre recombinase cardiotoxicity^[@R31]--[@R33]^. *SalvCKO* mice included tamoxifen-injected αMHC-mcm; ROSA^mT/mG^; *Salv^fl/fl^* mice and tamoxifen-injected αMHC-mcm; *Salv^fl/fl^* mice. The ROSA^mT/mG^ reporter was used to linage trace αMHC-mcm cardiomyocytes. Tamoxifen-injected αMHC-mcm; *Rpl22^HA^* mice were used as controls for TRAP experiments. For experiments involving TRAP *SalvCKO* mice, we used tamoxifen-injected αMHC-mcm; *Salv^fl/fl^*; *Rpl22^HA^* mice. For the P1 Park2 experiments, we used C57BL/6J and *Park2^tm1shn/j^* mice. For the P8 and adult double mutant experiments, we used αMHC-mcm; *Salv^fl/fl^*; *Park2^tm1shn/j^* mice injected with tamoxifen.

To achieve recombination of floxed alleles in the adult mice, tamoxifen dissolved in peanut oil was administered via intraperitoneal injection at a dose of 1 mg/day for 4 days beginning 3 weeks post-MI. No tamoxifen was administered to the mice in the P1 experiments. To achieve recombination of the floxed alleles in the P8 mouse experiments, tamoxifen was administered at P7, P8, P9, and P10, at 0.5 mg/day dissolved in peanut oil, as previously described^[@R8]^.

All mouse procedures were performed in accordance with institutional and governmental guidelines, and approved by the Baylor College of Medicine Institutional Animal Care and Use Committee.

Surgical Procedures {#S4}
-------------------

### Model of heart failure in adult mice {#S5}

To induce MI in 8- to 10-week-old mice, we permanently ligated the LAD artery as previously described^[@R8]^. Briefly, mice were anesthetized with 2% isoflurane and then intubated. We exposed the heart by performing a thoracotomy through the fourth or fifth intercostal space and tied an 8-0 nylon suture around the LAD artery. The mice were allowed to recover for 3 weeks, and then heart function was analyzed by using echocardiography. Because the clinical definition of heart failure is a 20% reduction in left ventricular EF as indicated on echocardiography (i.e., from \>50% EF to \<40% EF in humans),^[@R34]^ only mice with a \>20% decrease in left ventricular ejection fraction were included in the study^[@R13]^. Our observed rates of survival (64%) and inclusion (70%) were consistent with those previously reported (50%-60% and 54%-92%, respectively)^[@R13],[@R34],[@R35]^.

### Model of myocardial infarction in early and late neonatal mice {#S6}

To induce MI in neonatal mice, we permanently ligated the LAD artery on postnatal day 1 (P1) or postnatal day 8 (P8), as previously described^[@R8]^. Briefly, mice were anesthetized with hypothermia, the heart was exposed via thoracotomy through the fourth or fifth intercostal space, and an 8-0 nylon suture was tied around the LAD coronary artery.

Echocardiography {#S7}
----------------

Cardiac function was determined by echocardiography (VisualSonics, Vevo 2100, 40Mhz-550S probe). After alignment in the transverse B-mode with the papillary muscles, cardiac function was measured on M-mode images.

Injury regions {#S8}
--------------

Cardiac tissue regions used for RNA, or image characterization described as; whole heart (WH), ischemic zone (IZ, LV free wall), border zone (BZ, LV anterior and posterior wall), or distal zone (DZ, interventricular septum).

Histological analysis {#S9}
---------------------

Whole hearts were fixed with 10% formalin, embedded in paraffin, and sectioned at 7-μm intervals. Each slide had 10 sections, which started at the apex and ended at the suture ligation site (approximately 50 slides). Every 4th slide was stained with Masson's trichrome to identify areas of fibrosis. To determine scar size we examined serial sections from the apex to the ligation suture site and calculated the average percent fibrosis of the midline circumference around the LV^[@R36]^. To quantify cardiomyocytes we used PCM-1 immunostaining and methods as described^[@R37]^.

Immuno-fluorescence Experiments {#S10}
-------------------------------

To assess cell cycle entry, we added thymidine analogs to the drinking water for a duration of 4 days prior to dissection. The analog 5-iodo-2′-deoxyuridine (IdU; 0.2 g/L, MP Biomedical, catalog \#0210035701) was used at the 3 week post-MI time point prior to tamoxifen delivery. The analog 5-ethynyl-2′-deoxyuridine (EdU; 0.2 g/L, Santa Cruz, catalog \#sc-284628A) was used for the 4, 6, and 9 weeks post-MI time points. IF experiments were performed on FFPE (formalin-fixed and paraffin-embedded sections) or on fresh frozen optimum cutting temperature-embedded sections. The stains and antibodies used for these experiments included; Click-iT EdU kit, IdU staining (IdU cross-reactive BrdU antibody, BD Biosciences, 347580), mTmG lineage trace (endogenous mTomato and mGFP fluorescence), isolectin B4 (Vector Labs, FL-1201), CD31 antibody (Pecam, BD Pharmingen, 550274), PCM1 (Sigma, HPA023370), cTnT (ThermoFisher, MS295), wheat germ agglutinin (WGA, Vector Labs, RL-1022), and pHH3 (cell signaling, \#9701).

Linage tracing was done using the *Rosa26^mT/mG^* reporter at 4 and 9 weeks post-MI in the BZ. A full dose of tamoxifen was administered, and mosaicism of the reporter was observed in the BZ. Mosacism was not observed in the DZ. We assume this is due to the variability of drug-included cre activity because of the poor BZ vascularity. The 4 weeks post-MI time point was used as a baseline to determine cre activity in the BZ. The.

RNA {#S11}
---

### Total RNA {#S12}

Using trizol reagent, we isolated total RNA from the non-fibrotic myocardium (interventricular septum, anterior and posterior free wall) bellow the ligation suture.

### Translating ribosomal affinity purification (TRAP RNA) {#S13}

The TRAP method utilizes an inducible HA epitope-tagged ribosomal allele for the Cre-mediated cell-specific isolation of RNA^[@R38]^. By crossing this allele into the *SalvCKO* background and then performing TRAP-seq, we enriched for mRNAs that were loaded onto ribosomes in cardiomyocytes and determined the cardiomyocyte translating RNA profile. We quickly excised the whole heart from each mouse and obtained the LV anterior and posterior free-walls (the myocardial border zone) below the ligation suture to isolate ribosomal-associated cardiomyocyte-specific RNA. The tissue was homogenized on ice in 1 mL of supplemented homogenization buffer (1% NP-40, 0.1M KCl, 0.05M Tris, 0.012M MgCl~2~, 0.1mg/mL cyclohexamide, protease inhibitors, RNAsin, 0.01M DTT). The samples were centrifuged, and the supernatants were incubated at 4°C for 4 hours with the primary HA-antibody (Cell Signaling, catalog \#3724) and then overnight with protein-G magnetic beads (Pierce, catalog \#88847). Bead-antibody RNA isolation was performed on the homogenate, which was washed with a high-salt buffer (1% NP-40, 0.3M KCl, 0.05M Tris, 0.012M MgCl~2~, 0.1mg/mL cyclohexamide, 0.01M DTT). In samples with no expression of the Rpl22^HA^ transgene, we recovered less than 1% of the total input RNA; therefore, we assumed that the RNA isolation was highly specific.

### Real Time - quantitative PCR (RT-qPCR) {#S14}

Transcript levels were quantified by using RT-qPCR. First-strand synthesis was performed by using iScript reverse transcription super mix for RT-qPCR (BioRad, catalog \#1708841); then, qPCR was carried out by using iTaq Universal SYBR Green super mix (BioRad, catalog \#172-5121). All qPCR primers are listed in [Supplementary Information Table 1](#SD1){ref-type="supplementary-material"}.

### RNA-seq library preparation and data analysis {#S15}

To isolate mRNA from Total RNA and TRAP RNA samples, we used the Dynabeads mRNA DIRECT Micro kit. ERCC Ex Fold RNA Spike-In control mixes were added before mRNA purification. Ion Torrent RNA-seq libraries were prepared with the Ion Total RNA-Seq kit v2 for whole transcriptome libraries. RNA sequencing was performed by using the Ion Proton system for next-generation sequencing. Reads were mapped to the mouse genome (mm10) and read counts quantified using STAR (version 2.5). Differentially expressed genes were detected using R package DESeq2 with the following parameters: threshold p ≤ 0.05, fold change ≥ 0.5, and FDR ≤ 10%. GO analysis was performed on differentially expressed genes (p\<0.05) with the Metascape online platform, and annotation clusters with terms that had a p-value ≤ 0.05 were included.

We compared our TRAP vs Total RNA analysis to the cardiomyocyte and non-cardiomyocyte isolation data set (GSE49906)^[@R39]^. When sorted by fold change, the top 400 cardiomyocyte-enriched genes extracted from the GSE49906 P60 mouse hearts, were on average 1.5 fold more highly expressed in TRAP-seq samples than in Total RNA-seq samples. Likewise, the top 400 non-cardiomyocyte enriched genes were on average 1.5 fold more highly expressed in the Total RNA-Seq data.

AAV9 targeting Salvador {#S16}
-----------------------

First, three siRNA constructs targeting *Salv* were tested *in vitro* in primary isolated neonatal mouse cardiomyocytes. Then, a triple short hairpin (sh)RNA construct with flanking miR30 sequences was cloned into the pENN.AAV.cTNT, p1967-Q vector downstream of GFP. Expression of both the GFP and the shRNA's is driven by the cardiac troponin T promotor. The miR30-based shRNA design allows for efficient shRNA expression from an RNA Pol II promotor^[@R40]^. The resulting construct was packaged into the muscle-trophic serotype AAV9 by the IDDRC Neuroconnectivity Core at Baylor College of Medicine. Two methods of viral delivery were used: direct myocardial injection at the time of MI (*Salv* KD-MI), or systemic injection by retro-orbital injection 3 weeks post-MI (*Salv* KD 3 weeks post-MI). Viral titer for efficient knockdown was done as described previously and shown to effectively knock down *Salv*^[@R41]^. For direct myocardial injection at the time of MI, the mice were given 2 or 3 intra-myocardial injections by using a Hamilton syringe (50μL capacity) with a 33-gauge needle to deliver a total of 2×10\^11 viral genomes (10 μl total volume delivered) into the ischemic risk area. In a separate cohort of mice, AAV9 was injected systemically via retro-orbital injection to deliver a total of 1×10\^12 viral genomes (50μL total volume delivered).

Statistical analysis {#S17}
--------------------

Throughout this study, we used either the Mann-Whitney U test or analysis of variance (ANOVA) with Tukey' pairwise post-hoc test or Bonferroni's post-hoc test to compare means and the F test to compare variance. All error bars show the standard error of the mean. Mice were assigned unique identifiers to blind experimenters to genotypes. A block randomization scheme was used to assign animals to groups on a rolling admissions basis to obtain adequate samples for each time point and each experiment. For echocardiography sample sizes were estimated using power analysis determined from our previously described experiments.

Data Availability {#S18}
-----------------

The sequencing data in this manuscript is available through the accession number on GEO: GSE100532.

Extended Data {#S19}
=============

![Activated Hippo signaling in Human HF\
**a-c**, Western blots human heart samples. Ctrl: nonfailing nontransplantable, n=6 **(a-c)**. HF: nonischemic idiopathic cardiomyopathy in end-stage heart failure, n=6 **(a, b)**. iHF: ischemic heart in end-stage heart failure, n=6 (**c**). Quantification presented in [Figure 1](#F11){ref-type="fig"}.](nihms902318f1){#F1}

![Mouse model of systolic heart failure\
**a-d,** Systolic diameter (**a**), diastolic diameter (**b**), systolic volume (**c**) and diastolic volume (**d**), n values indicated in [Fig. 1a](#F11){ref-type="fig"}, ANOVA Tukey post-test. **e, f**, H&E edema liquid (pink transudate fluid) in lung tissue three weeks post-MI, sham (n=3) (**e**) and MI (n=5) (**f**), scale = 50 μm. **g, h**, Prussian blue hemosiderin (blue) in lung tissue three weeks post-MI, sham (n=3) (**g**) and MI (n=5) (**h**), scale = 50μm. **i**, BNP (Natriuretic Peptide B) in blood serum three weeks post-MI, Mann Whitney (**i**). **j**, Weight gain three weeks post-MI (**j**), t-test. **k, l**, Longitudinal echocardiography beginning 3 weeks post-MI, data are a subset of [Fig. 2c](#F12){ref-type="fig"}. Ctrl Sham and Ctrl MI samples were split by Cre genotype or by injection type, indicated in parenthesis **(k)**. No significant effect of Cre or tamoxifen (Tam) was observed, ANOVA Tukey post-test **(k)**. Data: mean ± s.e.m, p-values \>0.05 nonsignificant (n.s.), \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](nihms902318f2){#F2}

![Histologic analysis at 3 weeks post-MI\
Masson's Trichrome of serial sagittal sections 3 weeks post-MI, no tamoxifen was delivered, genotype indicated, n=3/group, scar boundaries (open arrows), cardiomyocytes in the ischemic region (solid arrows), scale = 2 mm.](nihms902318f3){#F3}

![Histologic analysis at 4 weeks post-MI\
Masson's Trichrome of serial sagittal sections 4 weeks post-MI, 1 week post-tamoxifen, Ctrl (αMHC-mcm; mTmG) and *SalvCKO* (αMHC-mcm; mTmG; *Salv^fl/fl^*), n=3/group, scar boundaries (open arrows), cardiomyocytes in the ischemic region (solid arrows), scale = 2 mm.](nihms902318f4){#F4}

![Histologic analysis at 6 weeks post-MI\
Masson's Trichrome of serial sagittal sections 6 weeks post-MI, 3 weeks post-tamoxifen, Ctrl (αMHC-mcm; mTmG) and *SalvCKO* (αMHC-mcm; mTmG; *Salv^fl/fl^*), n=3/group, scar boundaries (open arrows), cardiomyocytes in the ischemic region (solid arrows), scale = 2 mm.](nihms902318f5){#F5}

![Vessel growth in the border zone of Hippo deficient mouse hearts\
**a**, Quantitative real-time PCR (qPCR) of known markers of heart Failure at 6 weeks post-MI, Myosin Heavy chain 6 (*Myh6*), Myosin heavy Chain 7 (*Myh7*), Natriuretic Peptide A (*Nppa*), Natriuretic Peptide B (*Nppb*), n=3/group, ANOVA Bonferroni post-test. **b**, Masson's Trichrome (scale=100μm) and IF staining for isolectin B4 (scale = 25μm) and CD31 (scale = 25μm), Ctrl (n=3) SalvCKO (n=5). **c-e**, Quantification 9 weeks post-MI in the BZ for capillary density **(c)**, isolectin+ vessels **(d)**, and CD31+ cells **(e)**, Ctrl (n=3) SalvCKO (n=5), Mann-Whitney. **f**, qPCR of angiogenic growth factors, cardiomyocyte-specific TRAP RNA, 6 weeks post-MI, Angiopoietin 1 (*Angpt1*) and 2 (*Angpt2*), fibroblast growth factor 14 (*Fgf14*) & 18 (*Fgf18*), Vascular endothelial growth factor b (*Vegfb*) & c (*Vegfc*), n=3/group, ANOVA Bonferroni post-test. Data: mean ± s.e.m, p-values \>0.05 nonsignificant (n.s.), \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](nihms902318f6){#F6}

![TRAP RNA sequencing reproducibility\
**a**, Reproducibility correlation matrices of the RNAseq read count, linear regression, n=3/group. **b, c**, Plot of the per-gene standard deviation (sd) across samples, against the rank (mean) and read count, variance stabilizing transformation, Total RNAseq (**b**), Trap RNAseq **(c)**. **d**, Log2FoldChange values between Trap and Total RNA-Seq for Ctrl-MI and SalvCKO-MI were highly correlated.](nihms902318f7){#F7}

![A reparative molecular response to heart failure in Hippo-deficient hearts\
**a**, Gene lists of the top 10 genes with the highest fold change in each GO category for Total RNA: *SalvCKO* MI vs Ctrl MI. **b**, Boxplot of the normalized read count for *Tnnt2*, *Cdh5*, and *Malat1*. **c**, Volcano plot TRAP-Seq: Ctrl MI vs Ctrl Sham. **d, e**, Gene ontology (GO) upregulated **(d)** and downregulated **(e)** genes. **f, g**, Gene lists of the top 10 genes with the highest fold change in each GO category for Trap RNA: Ctrl MI vs Ctrl Sham **(f)**, Trap RNA: *SalvCKO* MI vs Ctrl MI **(g)**.](nihms902318f8){#F8}

![Requirement of Park 2 in the regenerating mouse heart\
**a-c**, Human heart western blots, quantification presented in [Figure 4](#F14){ref-type="fig"}, Tubulin blot is repeated from [Extended Data Fig. 1](#F1){ref-type="fig"}. **d**, Scar size 21 days post-MI in P1 *Park2* wild-type (+/+) and null (−/−) mice, Mann-Whitney. **e, f**, Echocardiography: ejection fraction (EF) (**e**), and fractional shortening (FS) (**f**), ANOVA Bonferroni post-test. **g**, Cardiomyocyte cell size measured by cross-sectional area, mean (red dashed line), t-test. **h**, Masson's trichrome, 21 days post-MI in P1 *Park2* wild type (+/+) (n=8) and null (−/−) (n=4) mice, scale = 2mm. **i**, Summary of results indicating *Park2* is necessary for cardiac regeneration. Data: mean ± s.e.m, p-values \>0.05 nonsignificant (n.s.), \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](nihms902318f9){#F9}

![Requirement of Park 2 in the P8 Hippo-deficient regenerating mouse heart\
**a,** Mitochondrial DNA content 4 days post-MI in P8 Ctrl and *SalvCKO* (n=3/group). **b**, Park2 protein levels in border zone (BZ) and distal zone (DZ) myocardium at 4 days post-MI in P8 Ctrl and *SalvCKO* (n=3/group). **c**, Scar size 21 days post-MI in P8 *Park2* wild type (+/+) and mutant (mut; −/− or +/−) mice, in combination with *Salv* cKO, ANOVA Bonferroni post-test. **d, e**, Echocardiograpy: ejection fraction (EF) (**d**), and fractional shortening (FS) (**e**), ANOVA Bonferroni post-test. **f**, Masson's trichrome, 21 days post-MI in P8 *Park2* mutant (n=20) and *Salv* cKO; *Park2* double mutant mice (n=15), scale = 2mm. **g**, Summary of results indicating *Park2* is necessary for regeneration. Data: mean ± s.e.m, p-values \>0.05 nonsignificant (n.s.), \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](nihms902318f10){#F10}

Supplementary Material {#S20}
======================

Supported by grants from the National Institutes of Health (DE023177, HL127717, HL130804, HL118761 \[J.F.M.\]; and 5T32HL007676-23 \[J.P.L.\]), Vivian L. Smith Foundation (J.F.M.), State of Texas funding (J.F.M. & J.T.W), LeDucq Foundation Transatlantic Networks of Excellence in Cardiovascular Research (14CVD01) "Defining the genomic topology of atrial fibrillation." (J.F.M.). Supported by IDDRC grant number 1U54 HD083092 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and the Mouse Phenotyping Core at Baylor College of Medicine (U54 HG006348). T.H. was supported by American Heart Association Scientist Development Grant (16SDG26460001). Also supported in part by Neuroconnectivity core and Optical Imaging and Vital Microscopy core at Baylor College of Medicine. Nicole Stancel, PhD. ELS provided editorial assistance.

**Author Contributions:**

J.P.L, J.T.W., and J.F.M conceived and designed experiments and interpreted data. J.P.L, T.H, M.Z, M.C.H, Y.M. and M.R. performed experiments. J.P.L and J.F.M. analyzed data and compiled figures. A.S. provided human tissue samples J.P.L., J.T.W., and J.F.M wrote and edited the manuscript.

The authors have no competing financial interest to declare.

![Activated Hippo signaling in human HF\
**a, b**, Western blots human heart samples. Ctrl: nonfailing nontransplantable, n=6; HF: nonischemic idiopathic end-stage cardiomyopathy, n=6; iHF: ischemic end-stage HF, n=6. Additional samples [Extended Data Figure 1](#F1){ref-type="fig"}. **c-f**, Quantification Yap (**c**), pYap (**d**), pLats (**e**), Salv (**f**). Mann-Whitney. Data: mean ± s.e.m, p-values \>0.05 nonsignificant (n.s.), \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](nihms902318f11){#F11}

![HF reversal and cardiomyocyte renewal in *SalvCKO* mice\
**a**, Experimental timeline. Numbers/group analyzed by echocardiography. **b, c**, Fractional shortening (FS) (**b**) ejection fraction (EF) (**c**), ANOVA Tukey post-test. **d, e**, Masson's trichrome serial sections 9 weeks post-MI, n=7/group. scar boundaries (open arrows); ischemic region (solid arrows). Scar categories I, II, III. Scale = 2 mm. **f**, LV scar size, n=7/group, Mann-Whitney. **g**, Fibrosis and function: second order polynomial fit. **h**, Diagram cardiac regions. **i**, **j**, PCM-1 IF (**i**), scale = 100μm; quantification **(j)**, n=3/group, Mann-Whitney**. k**, **l**, EdU-labeled cardiomyocytes (arrow) (**k**) scale = 25μm; quantification (**l**), *SalvCKO* MI: 3 weeks (n=4), 9 weeks (n=5), others (n=3), ANOVA Bonferroni post-test. **m**, **n**, pHH3 IF (arrow) (**m**) scale = 25μm; quantification (**n**), n=3/group, Mann Whiteny. **o, p**, BZ lineage labeling (**o**), scale = 25μm; quantification (**p**), n=3/group, ANOVA Bonferroni post-test. **q**, Cardiomyocyte cross-sectional area whole heart(WH) and BZ 9 weeks post-MI, Ctrl MI (n=3) *SalvCKO* MI (n=5), ANOVA Bonferroni post-test. Control: tamoxifen-injected αMHC-mcm; ROSA^mT/mG^. *SalvCKO*; tamoxifen-injected αMHC-mcm; ROSA^mT/mG^; *Salv^fl/fl^*. Data: mean ± s.e.m, p-values \>0.05 nonsignificant (n.s.), \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](nihms902318f12){#F12}

![*SalvCKO* mice activate reparative molecular response to HF\
**a**, Total RNA-Seq diagram. **b**, Volcano plot Total RNA-Seq: *SalvCKO* MI, Ctrl MI (n=3/group). **c, d**, Gene ontology (GO) Total RNA-Seq: *SalvCKO* MI, Ctrl MI (n=3/group). **e**, TRAP RNA-Seq (TRAP-Seq) diagram. **f**, Volcano plot TRAP-Seq: *SalvCKO* MI, Ctrl MI (n=3/group). **g**, Sample distance matrix: Total RNA-Seq, TRAP-Seq (n=3/group). **h**, Fold change TRAP/Total RNA (n=3/group) cardiomyocyte, noncardiomyocyte-enriched genes (GSE49906), t-test, \*\*\*p\<0.001. **i**, Cardiomyocyte transcripts TRAP-Seq enriched; non-cardiomyocyte and non-coding RNA transcripts Total RNA-Seq enriched (n=3/group). **j**, PCA Total and TRAP-Seq (n=3/group). **k, l**, GO TRAP-seq: *SalvCKO* MI vs Ctrl MI (n=3/group). **m**, Normalized *Park2* read counts, n=3/group. Control: tamoxifen-injected αMHC-mcm; *Rpl22^HA^*. *SalvCKO*: tamoxifen-injected αMHC-mcm; *Rpl22^HA^*; *Salv^fl/fl^*.](nihms902318f13){#F13}

![*Park2* in HF and *Salv* gene therapy\
**a,b** Western blot human heart (**a**) and quantification(**b**), Mann-Whitney. (Tubulin^\#^ from [Figure 1a,b](#F11){ref-type="fig"} (n=6); additional samples [Extended Data Figure 1](#F1){ref-type="fig"}). **c, d**, fractional shortening (FS) (**c**) ejection fraction (EF) (**d**), ANOVA Tukey post-test, Ctrl Sham^†^, Ctrl MI^†^, *SalvCKO* Sham^†^, *SalvCKO* MI^†^ repeated from [Figure 2a-c](#F12){ref-type="fig"}. **e, f**, Masson's trichrome: *Park2*^−/−^ (n=3) **(e)** *Park2*^−/−^; *SalvCKO* (n=4) **(f)** 9 weeks post-MI. Scale = 2 mm. **g**, LV scar size, Ctrl MI^‡^, *SalvCKO* MI^‡^ repeated from [Figure 2f](#F12){ref-type="fig"} (n=7). **h**, Knockdown (KD) efficiency *Salv* siRNA, n=3/group. **i**, AAV9 diagram. **j, k**, FS (**j**) and EF (**k**), ANOVA Tukey post-test. **l, m**, GFP expression *Salv* KD BZ (n=3/group), Low GFP (Arrow), scale = 50μm. **n, o**, EdU-labeled cardiomyocytes (arrow), scale = 50μm; quantification **(o)**, n=3/group, Mann-Whitney. Data: mean ± s.e.m, p-values \>0.05 nonsignificant (n.s.), \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](nihms902318f14){#F14}
